- Home
- DSP vs SKYE Comparison
DSP vs SKYE Comparison
Compare DSP & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- SKYE
- Stock Information
- Founded
- DSP 1999
- SKYE 2012
- Country
- DSP United States
- SKYE United States
- Employees
- DSP N/A
- SKYE N/A
- Industry
- DSP EDP Services
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- DSP Technology
- SKYE Health Care
- Exchange
- DSP Nasdaq
- SKYE Nasdaq
- Market Cap
- DSP 220.3M
- SKYE 73.4M
- IPO Year
- DSP 2021
- SKYE N/A
- Fundamental
- Price
- DSP $13.78
- SKYE $4.52
- Analyst Decision
- DSP Strong Buy
- SKYE Buy
- Analyst Count
- DSP 8
- SKYE 6
- Target Price
- DSP $21.75
- SKYE $16.60
- AVG Volume (30 Days)
- DSP 242.9K
- SKYE 2.0M
- Earning Date
- DSP 08-11-2025
- SKYE 08-08-2025
- Dividend Yield
- DSP N/A
- SKYE N/A
- EPS Growth
- DSP N/A
- SKYE N/A
- EPS
- DSP 0.13
- SKYE N/A
- Revenue
- DSP $306,484,000.00
- SKYE N/A
- Revenue This Year
- DSP $18.36
- SKYE N/A
- Revenue Next Year
- DSP $15.95
- SKYE N/A
- P/E Ratio
- DSP $106.28
- SKYE N/A
- Revenue Growth
- DSP 30.64
- SKYE N/A
- 52 Week Low
- DSP $8.70
- SKYE $1.14
- 52 Week High
- DSP $26.33
- SKYE $7.60
- Technical
- Relative Strength Index (RSI)
- DSP 53.27
- SKYE 74.70
- Support Level
- DSP $12.79
- SKYE $3.41
- Resistance Level
- DSP $13.72
- SKYE $5.75
- Average True Range (ATR)
- DSP 0.61
- SKYE 0.60
- MACD
- DSP 0.08
- SKYE 0.17
- Stochastic Oscillator
- DSP 95.48
- SKYE 69.27
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.